253 related articles for article (PubMed ID: 33167494)
1. Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors.
Rodrigues Moita AJ; Bandolik JJ; Hansen FK; Kurz T; Hamacher A; Kassack MU
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167494
[TBL] [Abstract][Full Text] [Related]
2. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
3. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells.
Wilson AJ; Holson E; Wagner F; Zhang YL; Fass DM; Haggarty SJ; Bhaskara S; Hiebert SW; Schreiber SL; Khabele D
Cancer Biol Ther; 2011 Sep; 12(6):484-93. PubMed ID: 21738006
[TBL] [Abstract][Full Text] [Related]
4. Novel α,β-unsaturated hydroxamic acid derivatives overcome cisplatin resistance.
Pflieger M; Hamacher A; Öz T; Horstick-Muche N; Boesen B; Schrenk C; Kassack MU; Kurz T
Bioorg Med Chem; 2019 Oct; 27(19):115036. PubMed ID: 31431326
[TBL] [Abstract][Full Text] [Related]
5. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
[TBL] [Abstract][Full Text] [Related]
6. Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer.
Wilson AJ; Gupta VG; Liu Q; Yull F; Crispens MA; Khabele D
Neoplasia; 2022 Feb; 24(2):63-75. PubMed ID: 34933276
[TBL] [Abstract][Full Text] [Related]
7. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
Krieger V; Hamacher A; Cao F; Stenzel K; Gertzen CGW; Schäker-Hübner L; Kurz T; Gohlke H; Dekker FJ; Kassack MU; Hansen FK
J Med Chem; 2019 Dec; 62(24):11260-11279. PubMed ID: 31762274
[TBL] [Abstract][Full Text] [Related]
9. HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.
Lombardi R; Sonego M; Pucci B; Addi L; Iannelli F; Capone F; Alfano L; Roca MS; Milone MR; Moccia T; Costa A; Di Gennaro E; Bruzzese F; Baldassarre G; Budillon A
Mol Oncol; 2021 Apr; 15(4):1005-1023. PubMed ID: 33331136
[TBL] [Abstract][Full Text] [Related]
10. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
[TBL] [Abstract][Full Text] [Related]
11. The effect of sodium butyrate and cisplatin on expression of EMT markers.
Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M
PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577
[TBL] [Abstract][Full Text] [Related]
12. A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition.
Shee K; Wells JD; Ung M; Hampsch RA; Traphagen NA; Yang W; Liu SC; Zeldenrust MA; Wang L; Kalari KR; Yu J; Boughey JC; Demidenko E; Kettenbach AN; Cheng C; Goetz MP; Miller TW
Clin Cancer Res; 2020 Jan; 26(1):159-170. PubMed ID: 31558472
[TBL] [Abstract][Full Text] [Related]
13. Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells.
Zitzmann K; Ailer G; Vlotides G; Spoettl G; Maurer J; Göke B; Beuschlein F; Auernhammer CJ
Int J Oncol; 2013 Dec; 43(6):1824-32. PubMed ID: 24100469
[TBL] [Abstract][Full Text] [Related]
14. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
Fischer C; Leithner K; Wohlkoenig C; Quehenberger F; Bertsch A; Olschewski A; Olschewski H; Hrzenjak A
Mol Cancer; 2015 Jan; 14():4. PubMed ID: 25608569
[TBL] [Abstract][Full Text] [Related]
15. Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
Asfaha Y; Schrenk C; Alves Avelar LA; Lange F; Wang C; Bandolik JJ; Hamacher A; Kassack MU; Kurz T
Bioorg Med Chem; 2020 Jan; 28(1):115108. PubMed ID: 31787463
[TBL] [Abstract][Full Text] [Related]
16. Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model.
Taylan E; Zayou F; Murali R; Karlan BY; Pandol SJ; Edderkaoui M; Orsulic S
Gynecol Oncol; 2020 Oct; 159(1):277-284. PubMed ID: 32698955
[TBL] [Abstract][Full Text] [Related]
17. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
18. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
[TBL] [Abstract][Full Text] [Related]
19. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
Luszczek W; Cheriyath V; Mekhail TM; Borden EC
Mol Cancer Ther; 2010 Aug; 9(8):2309-21. PubMed ID: 20682643
[TBL] [Abstract][Full Text] [Related]
20. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]